1. Home
  2. BTU vs IMNM Comparison

BTU vs IMNM Comparison

Compare BTU & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peabody Energy Corporation

BTU

Peabody Energy Corporation

N/A

Current Price

$25.18

Market Cap

2.7B

Sector

Energy

ML Signal

N/A

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$19.52

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BTU
IMNM
Founded
2016
2006
Country
United States
United States
Employees
6600
N/A
Industry
Coal Mining
Medicinal Chemicals and Botanical Products
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.5B
IPO Year
2001
2020

Fundamental Metrics

Financial Performance
Metric
BTU
IMNM
Price
$25.18
$19.52
Analyst Decision
Buy
Strong Buy
Analyst Count
6
16
Target Price
$31.58
★ $35.20
AVG Volume (30 Days)
★ 2.1M
1.3M
Earning Date
10-29-2026
11-05-2026
Dividend Yield
★ 1.20%
N/A
EPS Growth
N/A
★ 51.40
EPS
★ N/A
N/A
Revenue
★ $3,861,500,000.00
$6,941,000.00
Revenue This Year
$10.31
N/A
Revenue Next Year
$9.42
$18,747.97
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$20.06
$13.53
52 Week High
$41.14
$30.06

Technical Indicators

Market Signals
Indicator
BTU
IMNM
Relative Strength Index (RSI) 45.11 30.12
Support Level $23.51 $19.39
Resistance Level $30.41 $23.48
Average True Range (ATR) 1.02 1.12
MACD -0.06 -0.27
Stochastic Oscillator 42.71 13.81

Price Performance

Historical Comparison
BTU
IMNM

About BTU Peabody Energy Corporation

Peabody Energy Corp is a producer of metallurgical and thermal coal. It also markets and brokers coal, both as principal and agent, and trades coal and freight-related contracts. The company operates in the following segment: Seaborne Thermal, Seaborne Metallurgical, Powder River Basin, Other U.S. Thermal and Corporate and Other. The Seaborne Thermal segment generates the majority of the revenue for the company. A substantial part of its overall revenue is generated from its customers in the United States, and rest from Japan, China, Australia, Taiwan, and other regions.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: